Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Should You Sell?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped down prior to trading on Tuesday . The stock had previously closed at $27.37, but opened at $25.6501. Chugai Pharmaceutical shares last traded at $26.68, with a volume of 325,235 shares trading hands.

Chugai Pharmaceutical Stock Down 2.4%

The stock has a market cap of $86.09 billion, a PE ratio of 32.70 and a beta of 0.63. The business has a 50 day moving average price of $25.00 and a 200 day moving average price of $24.11.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings results on Friday, October 24th. The company reported $0.23 earnings per share (EPS) for the quarter. The company had revenue of $2.26 billion during the quarter. Chugai Pharmaceutical had a return on equity of 20.63% and a net margin of 32.74%. On average, research analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.